Subfoveal choroidal neovascularisation

The PBS subsidises aflibercept, ranibizumab and verteporfin for patients with subfoveal choroidal neovascularisation due to age-related macular degeneration.

Aflibercept, ranibizumab and verteporfin can be subsidised through the PBS under section 85 of the National Health Act 1953 for patients with subfoveal choroidal neovascularisation due to age-related macular degeneration.

Patient eligibility

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing aflibercept, ranibizumab and verteporfin.

Patients must be treated by an ophthalmologist to be eligible for PBS subsidised treatment with these medications.

Applications

Initial treatment

Make all initial applications for authority approval to prescribe PBS subsidised aflibercept, ranibizumab and verteporfin for the treatment of patients with subfoveal choroidal neovascularisation in writing and:

All applications must include:

Continuing treatment

You can make an application for continuing treatment by calling the PBS Complex Drugs Programs enquiry line.

Emergency treatments only

To avoid a delay in starting treatment, you can fax the completed authority application form, authority prescription form and any relevant attachments to the PBS Complex Drugs Programs team, who will contact you by phone. You are no longer required to send the original authority prescriptions form, authority application form and any relevant attachments.

Further information

For more information contact the PBS Complex Drugs Programs enquiry line.

Page last updated: 1 October 2017